bluebird bio (BLUE) Tops Q4 EPS by 76c, Updates on BLA Submission for Lovo-Cel for Sickle Cell Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
March 29, 2023 7:00 AM EDT- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 7 patient starts (cell collections) across both programs to date -
- Update on Biologics License Application (BLA) submission for lovo-cel for sickle cell disease (SCD) -
- Management to host conference call today, March 29, 2023 at 8:00AM ET -
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent... More
